"乙肝"标签列表

Controversies in the Therapy of CHB–When to start?2007-12-07

Controversies in the Therapy of CHB–When to stop?2007-12-07

核苷类似物治疗HBeAg阴性患者，恩替卡韦优于拉米夫定2007-12-07

Asia Hep Symposium On Controversies in Therapy of Hepatitis B: When to Alter 2007-12-06

Controversies in the therapy of Hepatitis B Infection: When to Monitor2007-12-06

CONTROVERSIES IN THE THERAPY OF HEPATITIS B INFECTIONPREDICTOR OF COMPLICATIONS2007-12-06

辩论：核苷类似物VS聚乙二醇化干扰素初治HBeAg-阳性患者2007-12-05

慢性乙型肝炎抗病毒治疗耐药的研究的进展2007-11-28

《国际肝病》采访Gish教授2007-11-26

Treatment options for CHB2007-11-19

荷兰鹿特丹大学医学中心Janssen教授运用聚乙二醇干扰素α-2b治疗HBeAg阳性乙肝的临床试验2007-11-15

聚乙二醇干扰素α-2b治疗慢性乙肝2007-11-15

Predicting Sustained HBeAg Loss after Treatment with Peginterferon Alpha-2b: Development and (2)2007-11-14

Predicting Sustained HBeAg Loss after Treatment with Peginterferon Alpha-2b: Development and (1)2007-11-14

Long-Term, Low-Dose Treatment With Pegylated Interferon alfa-2b Leads to a Significant Reduction (3)2007-11-14

Long-Term, Low-Dose Treatment With Pegylated Interferon alfa-2b Leads to a Significant Reduction (4)2007-11-14

Long-Term, Low-Dose Treatment With Pegylated Interferon alfa-2b Leads to a Significant Reduction (2)2007-11-14

Long-Term, Low-Dose Treatment With Pegylated Interferon alfa-2b Leads to a Significant Reduction (1)2007-11-14

Effect of Infliximab on the Efficacy of Peginterferon alfa-2b(PEG-2b) Plus Ribavirin(RBV) (4)2007-11-14

Effect of Infliximab on the Efficacy of Peginterferon alfa-2b(PEG-2b) Plus Ribavirin(RBV) (2)2007-11-14